



Review Article

A Review of Ultrasound-Mediated Checkpoint Inhibitor Immunotherapy

Jocelyne Rivera^{a,b}, Antonia Digkila^c, Anna S. Christou^a, James Anibal^{a,d}, Katherine A. Vallis^e,
Bradford J. Wood^a, Eleanor Stride^{b,*}

^a Center for Interventional Oncology, Interventional Radiology, National Institutes of Health Clinical Center, National Cancer Institute, Bethesda, MD, USA

^b Botnar Research Centre, Institute of Biomedical Engineering, University of Oxford, Oxford, UK

^c Department of Oncology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland

^d Computational Health Informatics Lab, Institute of Biomedical Engineering, University of Oxford, Oxford, UK

^e Department of Oncology, University of Oxford, Oxford, UK



ARTICLE INFO

Over the past decade, immunotherapy has emerged as a major modality in cancer medicine. However, despite its unprecedented success, immunotherapy currently benefits only a subgroup of patients, may induce responses of limited duration and is associated with potentially treatment-limiting side effects. In addition, responses to immunotherapeutics are sometimes diminished by the emergence of a complex array of resistance mechanisms. The efficacy of immunotherapy depends on dynamic interactions between tumour cells and the immune landscape in the tumour microenvironment. Ultrasound, especially in conjunction with cavitation-promoting agents such as microbubbles, can assist in the uptake and/or local release of immunotherapeutic agents at specific target sites, thereby increasing treatment efficacy and reducing systemic toxicity. There is also increasing evidence that ultrasound and/or cavitation may themselves directly stimulate a beneficial immune response. In this review, we summarize the latest developments in the use of ultrasound and cavitation agents to promote checkpoint inhibitor immunotherapy.

Introduction

Cancer immunotherapy

Although there is evidence of the exploitation of the immune system in treating diseases in medical texts dating back to the Ancient World, the use of immunotherapy in oncology was not widely explored until the 18th century [1]. In 1863, Rudolf Virchow reported a connection between tumours and inflammation after observing that neoplastic tissues are often surrounded by leukocytes. Since then, deeper understanding of the inflammatory microenvironment of solid tumours has supported Virchow's hypothesis, and the correlation between malignant tissue and inflammation has spurred the development of cancer immunotherapy [2–5]—the harnessing of the body's natural defences to treat and prevent tumour growth. The most widely reported example of early cancer immunotherapy was the experiment by William B. Coley in 1891, in which he attempted to treat cancer patients with bacteria-derived products [1,6]. Coley [7] reported remarkable effects in certain cancer patients, but his lack of systematic reporting, inconsistent success rates and competition from the contemporaneous development of radiotherapy meant that his work remained largely ignored and indeed discredited for most of the 20th century. Decades later, interest in the

immune system re-emerged following advances in immunology and cancer research, including the discovery of interferon and dendritic cells [8,9], understanding of the crucial role of T cells in immunity [10] and development of the first vaccine based on a single purified surface antigen [11,12]. Over the past 40 years the field of immunology has emerged as a major influence in cancer research and treatment. In 2018, James P. Allison and Tasuku Honjo were jointly awarded the Nobel Prize in Physiology or Medicine “for their discovery of cancer therapy by inhibition of negative immune regulation” [13].

Immunotherapeutics

In cancer immunotherapy, agents are utilized to either activate or boost the immune system to attack cancer cells through natural mechanisms, which otherwise are evaded, are repressed or never develop at all enabling uninterrupted disease progression [14] (Figs. 1 and 2).

In recent years, a wide variety of immunotherapeutic products have been approved by the U.S. Food and Drug Administration (FDA), including checkpoint inhibitors, recombinant cytokines, adoptive cell therapies and cancer vaccines (Fig. 2). To date, immune checkpoint inhibitors represent the most thoroughly investigated class of immunotherapeutics. Current mainstream drugs that block checkpoint proteins target CTLA-4 (cytotoxic T lymphocyte-associated protein 4), PD-1

* Corresponding author. Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Headington, Oxford OX3 7LD, UK.
E-mail address: eleanor.stride@eng.ox.ac.uk (E. Stride).




Figure 1. Effects of immune checkpoint inhibitors. Monoclonal antibodies that block the regulatory immune targets CTLA-4, PD-1 and PD-L1 are the mainstream drugs currently applied in the clinic. A deeper understanding of tumour immunology has led to an increasing number of immunotherapies, including the first recent U.S. Food and Drug Administration approval of anti-LAG-3. For tumour-directed T cells to become activated, two signals are required. The first signal corresponds to the binding of specific tumour peptides (TAA) to TCR on antigen-specific T cells. The second signal is typically mediated between the interaction of co-stimulatory molecules on antigen-presenting cells and T-cell receptors. Blocking immune checkpoint proteins, including PD-1, PD-L1, CTLA-4 and LAG-3, with monoclonal antibodies promotes increased T-cell activation, proliferation and enhanced effector function. After the monoclonal antibody binds to the immune targets, the tumour-specific killing ability of T cells is then activated (causing an immune attack) [15,16]. MHC, major histocompatibility complex; TAA, tumour-associated antigen; TCR, tumour cell receptor; IFN- γ , interferon- γ . Created in Biorender.com.

(programmed cell death protein 1) and PD-L1 (programmed cell death ligand 1) [6,19,20]. Whilst CTLA-4 and PD-1 are found on T cells, PD-L1 is found mainly on cancer cells [19]. The physiological role of immune checkpoints is to maintain appropriate immune responses and protect healthy tissues from auto-immune attack (Fig. 1). Over the past decade, the most impactful class of novel anti-tumour drugs comprises those that inhibit PD-1/PD-L1 [21–28]. These drugs block the binding of inhibitory molecules to their receptor ligand on tumour or cytotoxic T cells [29–31]. As of December 2021, the number of active interventional clinical trials testing the effectiveness of anti-PD-1/PD-L1 increased from 1 in 2006 to 5683 as monotherapy or in combination with other treatments [5,32]. In 2016, the first clinical trial of a PD-1-targeted monoclonal antibody, nivolumab, was reported (NCT01454102). Since then, at least seven monoclonal antibodies targeting PD-1 or its ligand PD-L1 have been approved by the FDA alone or in combination with other therapies for the treatment of more than 14 cancer types (Table 1).

In March 2022, the FDA approved a combination of nivolumab and relatlimab, the first immune checkpoint inhibitor targeting LAG-3 (lymphocyte-activation gene 3), for patients with untreated unresectable or metastatic melanoma [33].

Similar to Coley's toxins, however, the clinical success of immunotherapy has been variable, with only 20%–30% of patients responding to monotherapy, and some only temporarily. Solid tumours present a particular challenge, with the efficacy of anti-PD-1/PD-L1 inhibitors fluctuating between 10% and 30% [37,38]. The tumour microenvironment (TME) not only presents a physical barrier to drug uptake and accumulation; it also contributes directly to the suppression of a normal immune response through a number of mechanisms such as production of immunosuppressive cytokines and induction of regulatory T cells [39,40]. If a therapeutic concentration of an immunotherapeutic cannot be achieved, then there will be insufficient restoration of the anti-tumour immune response [41], development of resistance, tumour




Figure 2. Effects of microbubbles and ultrasound in enhancement of different classes of cancer immunotherapy. Immunomodulatory agents or immunotherapeutics can be categorised as follows. (i) Agents that promote the activity of dendritic cells, antigen-presenting cells (APCs) and/or T lymphocytes, to identify tumour cells as “foreign.” (ii) Agents that inhibit immunosuppressive responses in tumours: Such agents may inhibit myeloid-derived suppressor cells (MSDCs) or regulatory T cells (Tregs) or may inhibit the suppressive function of immune checkpoint molecules, including CTLA-4 (ipilimumab), PD-1 (pembrolizumab and nivolumab) and PD-L1 (atezolizumab, avelumab, durvalumab) [17]. (iii) Cellular therapies including chimeric antigen receptor (CAR) T cells, engineered T cell receptor (TCR) therapy, adoptive transfer of tumour-infiltrating lymphocytes (TILs) and cell-based vaccines. This illustration represents distinct categories of immunotherapy and how the effects of microbubbles and ultrasound could enhance each immunotherapy subclass. Reprinted, with permission, from Kooiman et al. [18].

Table 1

CTLA-4 and PD-1/PD-L1 targeted drugs (inhibitors of CTLA-4 and PD-1/PD-L1) approved by the U.S. FDA

Drug name (brand name, manufacturer)	Type of cancer approved to treat	First FDA approval date	Type of checkpoint inhibitor
Ipilimumab (Yervoy, BristolMeyersSquibb)	Melanoma, RCC, colorectal, HCC, NSCLC, malignant pleural mesothelioma	2011	Anti-CTLA-4
Pembrolizumab (Keytruda, Merck&Co)	Melanoma, NSCLC, RCC, Hodgkins lymphoma, HNSCC, Merkel cell carcinoma, MSI-H or dMMR markers, colorectal cancer, gastric cancer, HCC, cervical cancer, PMBCL, SCLC, cutaneous squamous, bladder cancer, breast cancer, endometrial cancer, esophageal cancer, TMB-high cancer	2014	Anti-PD-1
Nivolumab (Opdivo, Bristol-Myers Squibb)	Melanoma, NSCLC, RCC, Hodgkin's lymphoma, HNSCC, colorectal cancer, gastric cancer, HCC, SCLC, bladder cancer, esophagus, malignant mesothelioma	2014	Anti-PD-1
Atezolizumab (Tecentriq, Roche)	Melanoma, NSCLC, HCC, SCLC, bladder cancer, breast cancer	2016	Anti-PD-L1
Durvalumab (Imfinzi, AstraZeneca)	NSCLC, SCLC, bladder cancer, biliary track	2017	Anti-PD-L1
Avelumab (Bavencio, EMD Serono)	RCC, Merkel cell carcinoma, bladder cancer	2017	Anti-PD-L1
Nivolumab + ipilumab (Opdivo + Yervoy, Bristol-Meyers Squibb)	Malignant pleural mesothelioma, NSCLC	2020	Anti-CTLA-4 and anti-PD-1
Tremelimumab + durvalumab (Imjudo + Imfinzi, Pfizer/AstraZeneca Pharmaceuticals)	Metastatic NSCLC, no sensitizing EGFR mutation, anaplastic lymphoma kinase genomic tumour aberrations	2022	Anti-CTLA-4
Relatlimab-rmbw + nivolumab (Opdualag, Bristol-Meyers Squibb)	Unresectable or metastatic melanoma	2022	Anti-LAG-3 and anti-PD-1
Cemiplimab-rwlc (Libtayo, Regeneron)	NSCLC, cutaneous squamous-cell carcinoma	2022	Anti-PD-1
Dostarlimab-gxly (Jemperli, GlaxoSmithKline)	dMMR solid cancers, endometrial carcinoma	2023	Anti-PD-1

In addition to the FDA-approved drugs, a few more drugs have been approved by agencies of the European Union, Japan and China: camrelizumab, sintilimab, tislelizumab and toripalimab [32,34–36].

dMMR, DNA mismatch repair; EGFR, epidermal growth factor receptor; FDA, U.S. Food and Drug Administration; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell cancer; MSI-H, high microsatellite instability; NSCLC, non-small cell lung cancer; PMBCL, primary mediastinal B-cell lymphoma; RCC, renal cell carcinoma; SCLC, small cell lung cancer; TMB, tumour mutational burden.

progression and, in some cases, treatment-limiting side effects [42]. Therefore, a method that can either enable greater delivery efficiency and/or shift the TME from immunosuppressive to immunopermissive would have a major impact for many cancer patients who would otherwise fail immunotherapy [43]. The aim of this review is to discuss the potential application of ultrasound in this context to overcome the limitations of checkpoint inhibitor immunotherapy.

Ultrasound therapy and immunostimulation

High-intensity focused ultrasound

High-intensity focused ultrasound (HIFU, *i.e.*, ultrasound with sufficient intensity to promote tissue ablation) has been utilized in the treatment of multiple diseases, including essential tremor [44,45], uterine fibroids [46] and cancer [47–51]. Several studies have suggested that HIFU can also increase the effectiveness of immunotherapeutic drugs through enhanced delivery and/or by amplification of the natural anti-tumour immune response [52,53]. HIFU enables the local ablation of tumour tissue and can promote other beneficial effects in the TME [54] including a systemic or *abscopal* immune response [55]. For example, improved T lymphocyte-mediated function, measured by a marked increase in the CD4⁺/CD8⁺ ratio in peripheral blood of cancer patients with posterior choroidal melanoma, has been observed following hyperthermia generated by HIFU (frequency = 0.8 MHz, acoustic focal peak intensities ranging from 5000 to 20000 W/cm², duration ranging from 2.5 to 8 h) [41,56–58]. Currently, there is a growing number of ongoing pre-clinical studies supporting the rationale for combining immunotherapy with focused ultrasound [59]. Silvestrini et al. [60] combined ablative focused ultrasound with anti-PD-1 and CpG, a toll-like receptor (TLR) agonist, in murine B16 melanoma to induce an *abscopal* effect, resulting in a complete response to therapy in 80% of treated mice with bilateral disease at day 90. The underlying mechanisms have yet to be fully explained and are likely multifactorial, for example, enabling antigen release, promoting vascular alteration, chemokine, or cytokine alteration or dampened immune resistance. Interestingly, other physical cancer treatments such as surgery, microwave and external beam radiotherapy have also been reported to stimulate *abscopal* effects in pre-clinical and clinical studies [41,61–64], although similarly the underlying mechanisms have never been fully explained.

Ultrasound-mediated cavitation

High-intensity focused ultrasound can induce both thermal and mechanical effects. Of the latter, cavitation—the generation and subsequent oscillation of gas/vapour-filled bubbles—has been reported to be especially important in cancer therapy from accelerating ablative processes to facilitating uptake of chemotherapy [65,18]. In addition, anti-tumour immune responses may be activated by cavitation through potentiation of immunostimulatory or chemotactic factors or through their delivery into cells [52,66–69]. The presence of cavitation bubbles during the application of ultrasound may also lead to bio-effects in tumours such as (i) an increase in blood vessel permeability, (ii) alterations in the molecular composition of the TME, (iii) recruitment and penetration of tumour-infiltrating lymphocytes into tumour and (iv) enhanced extravasation of particles or therapeutics into the interstitial space (Fig. 2) [18,70]. It is also possible that cavitation promotes the release of structurally unaltered tumour-associated peptides, allowing presentation of tumour neoantigens [71].

Pulsed mode high-intensity focused ultrasound (pHIFU) in combination with checkpoint inhibitor immunotherapy has also recently been determined to improve anti-tumour effects compared with control subjects and with the treatments alone. In pulsed mode, exposures last milliseconds or shorter and use high peak negative pressure amplitudes (10–20 MPa) similar to the acoustic parameters used in histotripsy studies [72,73]. In a murine orthotopic model of pancreatic cancer, pHIFU in

combination with antibody immunotherapy shifted the TME from an immunosuppressive to a pro-inflammatory microenvironment by an increased ratio of CD8⁺ IFN γ ⁺ T cells to CD4⁺ T cells, regulatory T cells and MDSCs (peak negative pressure = 17 MPa, frequency = 1.5 MHz, duty cycle = 1%, 1 pulse/s, duration = 25 s) [74]. Acoustic cavitation and physical disruption of the tumours were also reported, and it was suggested that focused ultrasound in combination with checkpoint inhibitor immunotherapy may be able to enhance anti-tumour effects in patients with dense tumours, such as pancreatic cancer [74].

Localised drug delivery

Two key advantages of HIFU are that it can be applied extracorporeally, and the ultrasound beam can be tightly focused to localise tissue damage to the tumour site. Cavitation agents, including gas microbubbles, liquid droplets and solid particles [18], can be used to enable predictable generation of cavitation at the ultrasound focus and thus limit the risk of off-target effects. They can also be used to enable therapy to be delivered at lower, non-ablative ultrasound intensities. Microbubbles have been extensively used as image contrast agents for several decades, and more recently, clinical studies have reported their utility in restoring blood flow after myocardial infarction [75], disrupting the blood–brain barrier [76] and identifying liver lesions [77,78]. Clinical trials have also illustrated the safety and efficacy of ultrasound-triggered microbubble destruction combined with other cancer therapies, such as transarterial radioembolization [79,80].

Cavitation agents offer a means of further increasing treatment localisation by conjugating drug molecules to them to enable their release and/or tissue uptake at the target site. Microbubbles, in particular, can be readily engineered for disease-specific targeting and/or loaded with therapeutic agents to enable controlled drug release by low-intensity focused ultrasound (LIFU, *i.e.*, focused ultrasound with pulse intensity similar to that of diagnostic ultrasound) guided by imaging. Microbubble oscillations induced by LIFU can generate mechanical forces that cause vascular disruption and promote extravasation [70,81,82]. This is particularly important for cancer therapy as, unlike the vessels found in healthy tissue, tumour blood vessels are structurally disorganised [83], and low response rates to immunotherapy may be at least partly attributed to this aberrant vasculature [84]. Li et al. [82] designed and developed a multifunctional microbubble system that incorporated dual loading with a chemotherapeutic agent (Docetaxel) inside the lipid shell, and the anti-PD-L1 monoclonal antibody conjugated to the surface. This group suggested that the system exhibited improved delivery to the tumour site through three combined effects: (i) anti-PD-L1 conjugated to the microbubble surface allowed tumour targeting; (ii) low-intensity focused ultrasound collapsed the microbubbles and released the encapsulated chemotherapeutic agent within the tumour (acoustic focal peak intensity = 2.0 W/cm², frequency = 1 MHz, duty cycle = 50%, duration = 5 min); and (iii) cavitation increased tumour vessel permeability and enhanced drug penetration across the tumour vessel walls and interstitium [81]. Anti-PD-1 has been coupled to microbubbles for deployment by low-intensity ultrasound. This combination therapy amplified immune-tumour responses and increased survival compared with conventional delivery of free drug [31].

Immune adjuvants, including TLR agonists, have been used to enhance the therapeutic efficiency of immunotherapy [60,85]. Immune adjuvants are molecules that elicit activation of innate and adaptive immune responses by promoting recruitment of antigen-specific CD8⁺ T cells to tumour sites [85–87]. The mechanisms underlying immunostimulatory adjuvants for cancer immunotherapy are comprehensively detailed in other reviews and so are not specifically discussed here [88–91]. Despite the benefits of immunostimulatory adjuvants in cancer immunotherapy, however, the systemic administration of TLR agonists inevitably leads to an uncontrolled immune response and damage to healthy tissue [85,92]. Zheng et al. [85] recently reported a study indicating local administration of immune adjuvants by a drug-loaded

microbubble delivery system enhances checkpoint inhibitory immunotherapy (acoustic focal peak intensity = 1.5 W/cm^2 , frequency = 1.5 MHz , duty cycle = 50% , duration = 3 min). In this study, docetaxel and the immune adjuvant R837 were loaded into microbubbles and co-injected with the immune checkpoint inhibitor, anti-PD-L1. The tumour inhibition rate for primary and distant tumours reached $88.28 \pm 1.04\%$ and $89.86 \pm 5.76\%$, respectively, in the group receiving docetaxel, R837 and systemic delivery of anti-PD-L1 [85].

Anti-vascular effect


The combination of ultrasound and microbubbles has also been used as an “anti-vascular” agent to disrupt blood vessels with several downstream direct and indirect effects when combined with immunomodulators. These include potentially increased trafficking or penetration of immune checkpoint inhibitors (or resulting T cells) into tumour tissues or even enhanced processes for antigen-presenting cell maturation and differentiation. In a colorectal cancer murine model, ultrasound-mediated microbubble therapy induced necrosis via an instant shutdown of blood flow within the tumour tissue [31]. Another study reported cytokine recruitment of immune cells to both local and distant tumour sites in a Her2+ (NDL) murine breast cancer mouse model. This system produced anti-tumour effects via three pathways: (i) carriage of an anti-CD326 antibody to target tumour cells, (ii) sonoporation-enhanced transduction of a non-viral gene encoding IFN- β and (iii) tumour shrinkage by direct mechanical forces. Tumour transfection with IFN- β enhanced the damage-associated profile resulting from the destructive application of ultrasound to targeted microbubbles (frequency = 250 kHz , peak negative pressure = 500 kPa , burst length = 4 ms , pulse repetition frequency = 30 Hz , total duration = 3 min). The

combination of microbubbles with checkpoint inhibition reduced tumour growth in both the directly treated and distant tumours, inducing local and systemic immune effects [93].

Future perspectives

Clinical evidence has revealed that the combination of a PD-1/PD-L1 checkpoint inhibitor with a chemotherapeutic agent may be synergistic in specific clinical settings [82,94,95], and indeed, 90% of the new trials that started in 2020 involved combination strategies [96]. However, this combination approach has led to some quite severe side effects, including cardiotoxicity, hematotoxicity, hepatotoxicity and neurotoxicity. To address this challenge, the studies referred to in the previous section suggest that ultrasound-mediated cavitation may enhance the delivery of immunotherapeutic and chemotherapeutic agents while reducing toxicity compared with the free drug combination. Clinical studies are now ongoing to determine the efficacy of combining focused ultrasound with immunotherapy. A clinical trial evaluating the combination of focused ultrasound with pembrolizumab in solid tumours (AM-003/NCT04116320) is currently underway at the University of Virginia [59,97]. Another clinical trial also from the University of Virginia and investigating the combination of focused ultrasound with pembrolizumab in metastatic breast cancer patients (Breast-48/NCT03237572) was completed on 17 June 2022 but no results have been yet reported. Aside from these trials, there are others listed, recruiting or completed clinical studies worldwide exploring the use of focused ultrasound in combination with checkpoint inhibitors.

Combinations of anti-PD1/PD-L1 agents with anti-angiogenic or anti-vascular agents are also currently being tested in >80 ongoing clinical trials [98], and again, pre-clinical studies have determined a potential



role for ultrasound here too, through cavitation-enhanced delivery or direct ablation of the vasculature. Many questions remain, however, regarding the most effective combination of therapeutic modalities, including the optimization and choice of targeted therapies to enhance antigen presentation and cytotoxic T-cell priming in specific histology, indications or clinical scenarios [99]. A wide variety of checkpoint inhibitors and monoclonal antibodies are currently available in the clinic for cancer treatment. It is therefore of great importance to have a comprehensive scientific understanding of the mechanism(s) underlying the combination of ultrasound therapy and immunomodulation.

The cancer immunity cycle (Fig. 3) is a further key consideration to determine the appropriate timing of therapy delivery [19]. The different classes of immunotherapies face differing delivery challenges, and in many cases, their success relies mainly on the interaction with the targeted protein. These targets may focus on different time points in the linear evolution of a dynamic immune response or enhanced tumour immunity. In a syngeneic model of epithelial cancer [60], focal ultrasound therapy following immunotherapy resulted in increased number of leukocytes and CD8+ T cells, as compared with all control groups. Other studies have similarly concluded that, because of mechanical and immunological changes in the TME following local ablation, there may be an optimal window of opportunity for employing immunotherapy [31].

Two further important questions are whether a robust systemic immune response may be maintained without continued systemic exposure over time to an immunotherapeutic and whether there are any long-term adverse effects. Emerging evidence indicates that clinicians should be aware of the risk of chronic immune-related adverse events (irAEs) and their long-term outcomes, which are currently understudied in clinical trials [100].

Conclusions

Despite major advances in cancer immunotherapy, its widespread clinical success has been hindered by multiple factors, including cost, poor delivery efficiency and severe adverse effects in non-target organs. As a non-invasive and well-established clinical modality, ultrasound offers a potentially attractive means of addressing these challenges. Ultrasound ablation has been found to promote a systemic (abscopal) immune response and to enable potent anti-vascular effects. Ultrasound-mediated cavitation has similarly been found to promote a range of immunostimulatory effects and to both localise and enhance delivery efficiency of immunotherapeutics and/or other anti-cancer drugs. In recent years there have been numerous pre-clinical studies demonstrating therapeutic efficacy in a range of tumour models. The underpinning mechanisms, however, remain poorly understood and hence further work is required to identify optimal treatment regimens.

Conflict of interest

The authors declare no competing interests.

Acknowledgments

J.R. and J.A. are supported by the National Institutes of Health Centre for Interventional Oncology and the Intramural Research Program of the National Institutes of Health, National Cancer Institute, and the National Institute of Biomedical Imaging and Bioengineering. The authors would like to thank Susanne Kaesbauer for her assistance with the BioRender illustrations.

References

- [1] Eno J. Immunotherapy through the years. *J Adv Pract Oncol* 2017;8:747–53.
- [2] Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C–C chemokines. *Am J Pathol* 1997;150:1723–34.
- [3] Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet* 2001;357:539–45.
- [4] Samadi AK, Bilsland A, Georgakilas AG, Amedei A, Amin A, Bishayee A, et al. A multi-targeted approach to suppress tumor-promoting inflammation. *Semin Cancer Biol* 2015;35:S151–84.
- [5] Zhang JY, Yan YY, Li JJ, Adhikari R, Fu LW. PD-1/PD-L1 based combinational cancer therapy: icing on the cake. *Front Pharmacol* 2020;11:722.
- [6] Keisari Y. Tumor abolition and antitumor immunostimulation by physico-chemical tumor ablation. *Front Biosci (Landmark Ed)* 2017;22:310–47.
- [7] Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. *Clin Orthop Relat Res* 1991(262):3–11.
- [8] Isaacs A, Lindenmann J. Virus interference: I. The interferon. *Proc R Soc Lond B Biol Sci* 1957;147:258–67.
- [9] Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice: I. Morphology, quantitation, tissue distribution. *J Exp Med* 1973;137:1142–62.
- [10] Kiessling R, Klein E, Pross H, Wigzell H. "Natural" killer cells in the mouse: II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. *Eur J Immunol* 1975;5:117–21.
- [11] Beasley RP. Development of hepatitis B vaccine. *JAMA* 2009;302:322–4.
- [12] Dobosz P, Dzieciatkowski T. The intriguing history of cancer immunotherapy. *Front Immunol* 2019;10:2965.
- [13] Guo ZS. The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer). *BMC Cancer* 2018;18:1086.
- [14] Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. *Nat Rev Drug Discov* 2019;18:175–96.
- [15] Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. *Am J Cancer Res* 2020;10:727–42.
- [16] Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. *Cancer Discov* 2018;8:1069–86.
- [17] Labani-Motlagh A, Ashja-Mahdavi M, Loskog A. The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses. *Front Immunol* 2020;11:940.
- [18] Kooiman K, Roovers S, Langeveld SAG, Kleven RT, Dewitte H, O'Reilly MA, et al. Ultrasound-responsive cavitation nuclei for therapy and drug delivery. *Ultrasound Med Biol* 2020;46:1296–325.
- [19] Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity* 2013;39:1–10.
- [20] Sukari A, Nagasaka M, Al-Hadidi A, Lum LG. Cancer immunology and immunotherapy. *Anticancer Res* 2016;36:5593–606.
- [21] Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. *J Biomed Sci* 2017;24:26.
- [22] Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. *N Engl J Med* 2018;379:2220–9.
- [23] Goepfert K, Dinsart C, Rommelaere J, Foerster F, Moehler M. Rational combination of parvovirus H1 with CTLA-4 and PD-1 checkpoint inhibitors dampens the tumor induced immune silencing. *Front Oncol* 2019;9:425.
- [24] Inokuchi J, Eto M. Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma. *Cancer Manag Res* 2019;11:4519–28.
- [25] Nakamura Y. Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events. *Front Med (Lausanne)* 2019;6:119.
- [26] Sun X, Roudi R, Dai T, Chen S, Fan B, Li H, et al. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. *BMC Cancer* 2019;19:558.
- [27] Teufel A, Zhan T, Hartel N, Bornschein J, Ebert MP, Schulte N. Management of immune related adverse events induced by immune checkpoint inhibition. *Cancer Lett* 2019;456:80–7.
- [28] Wang C, Qiao W, Jiang Y, Zhu M, Shao J, Ren P, et al. Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer. *Cancer Med* 2019;8:4023–31.
- [29] Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711–23.
- [30] Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med* 2012;366:2455–65.
- [31] Bulner S, Prodeus A, Garipey J, Hynynen K, Goertz DE. Enhancing checkpoint inhibitor therapy with ultrasound stimulated microbubbles. *Ultrasound Med Biol* 2019;45:500–12.
- [32] Upadhaya S, Neftelinov ST, Hodge J, Campbell J. Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape. *Nat Rev Drug Discov* 2022;21:482–3.
- [33] Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. *Nat Immunol* 2023;24:1415–22.
- [34] Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. *AAPS J* 2021;23:39.
- [35] Borcoman E, Le Tourneau C. KEYNOTE-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer. *Ann Transl Med* 2020;8:1611.

- [36] Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. *Int Immunopharmacol* 2018;62:29–39.
- [37] Yu Y. Molecular classification and precision therapy of cancer: immune checkpoint inhibitors. *Front Med* 2018;12:229–35.
- [38] Adnan A, Munoz NM, Prakash P, Habibollahi P, Cressman ENK, Sheth RA. Hyperthermia and tumor immunity. *Cancers (Basel)* 2021;13:2507.
- [39] Wu F, Zhou L, Chen WR. Host antitumor immune responses to HIFU ablation. *Int J Hyperthermia* 2007;23:165–71.
- [40] Bandyopadhyay S, Quinn TJ, Scanduzzi L, Basu I, Partanen A, Tome WA, et al. Low-intensity focused ultrasound induces reversal of tumor-induced T cell tolerance and prevents immune escape. *J Immunol* 2016;196:1964–76.
- [41] Wu F, Wang ZB, Lu P, Xu ZL, Chen WZ, Zhu H, et al. Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. *Ultrasound Med Biol* 2004;30:1217–22.
- [42] Sharma P, Hu-Lieskova S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. *Cell* 2017;168:707–23.
- [43] Eranki A, Srinivasan P, Ries M, Kim A, Lazarski CA, Rossi CT, et al. High-intensity focused ultrasound (HIFU) triggers immune sensitization of refractory murine neuroblastoma to checkpoint inhibitor therapy. *Clin Cancer Res* 2020;26:1152–61.
- [44] Rohani M, Fasano A. Focused ultrasound for essential tremor: review of the evidence and discussion of current hurdles. *Tremor Other Hyperkinet Mov (NY)* 2017;7:462.
- [45] Wu P, Lin W, Li KH, Lai HC, Lee MT, Tsai KW, et al. Focused ultrasound thalamotomy for the treatment of essential tremor: a 2-year outcome study of Chinese people. *Front Aging Neurosci* 2021;13:697029.
- [46] Liu L, Wang T, Lei B. High-intensity focused ultrasound (HIFU) ablation versus surgical interventions for the treatment of symptomatic uterine fibroids: a meta-analysis. *Eur Radiol* 2022;32:1195–204.
- [47] He Y, Tan P, He M, Hu L, Ai J, Yang L, et al. The primary treatment of prostate cancer with high-intensity focused ultrasound: a systematic review and meta-analysis. *Medicine (Baltimore)* 2020;99:e22610.
- [48] Strunk HM, Henseler J, Rauch M, Mucke M, Kukuk G, Cuhls H, et al. Clinical use of high-intensity focused ultrasound (HIFU) for tumor and pain reduction in advanced pancreatic cancer. *Rofo-Fortschr Röntg* 2016;188:662–70.
- [49] Wu F, Wang ZB, Zhu H, Chen WZ, Zou JZ, Bai J, et al. Extracorporeal high intensity focused ultrasound treatment for patients with breast cancer. *Breast Cancer Res Treat* 2005;92:51–60.
- [50] Feril LB, Fernan RL, Tachibana K. High-intensity focused ultrasound in the treatment of breast cancer. *Curr Med Chem* 2021;28:5179–88.
- [51] Zhou B, He N, Hong J, Yang T, Ng DM, Gao X, et al. HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study. *BMC Surg* 2021;21:308.
- [52] Unga J, Hashida M. Ultrasound induced cancer immunotherapy. *Adv Drug Deliv Rev* 2014;72:144–53.
- [53] Shi G, Zhong M, Ye F, Zhang X. Low-frequency HIFU induced cancer immunotherapy: tempting challenges and potential opportunities. *Cancer Biol Med* 2019;16:714–28.
- [54] Joiner JB, Pylayeva-Gupta Y, Dayton PA. Focused ultrasound for immunomodulation of the tumor microenvironment. *J Immunol* 2020;205:2327–41.
- [55] Elhelf IAS, Albahar H, Shah U, Oto A, Cressman E, Almekkawy M. High intensity focused ultrasound: the fundamentals, clinical applications and research trends. *Diagn Interv Imaging* 2018;99:349–59.
- [56] Rosberger DF, Coleman DJ, Silverman R, Woods S, Rondeau M, Cunningham-Rundles S. Immunomodulation in choroidal melanoma: reversal of inverted CD4/CD8 ratios following treatment with ultrasonic hyperthermia. *Biotechnol Ther* 1994;5:59–68.
- [57] Wang X, Sun J. High-intensity focused ultrasound in patients with late-stage pancreatic carcinoma. *Chin Med J (Engl)* 2002;115:1332–5.
- [58] Curley CT, Sheybani ND, Bullock TN, Price RJ. Focused ultrasound immunotherapy for central nervous system pathologies: challenges and opportunities. *Theranostics* 2017;7:3608–23.
- [59] Sheybani ND, Price RJ. Perspectives on recent progress in focused ultrasound immunotherapy. *Theranostics* 2019;9:7749–58.
- [60] Silvestrini MT, Ingham ES, Mahakian LM, Kheirloomoom A, Liu Y, Fite BZ, et al. Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols. *JCI Insight* 2017;2:e90521.
- [61] Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. *Nat Rev Immunol* 2020;20:651–68.
- [62] Koury J, Lucero M, Cato C, Chang L, Geiger J, Henry D, et al. Immunotherapies: exploiting the immune system for cancer treatment. *J Immunol Res* 2018;2018:9585614.
- [63] Schade GR, Wang YN, D'Andrea S, Hwang JH, Liles WC, Khokhlova TD. Boiling histotripsy ablation of renal cell carcinoma in the Eker rat promotes a systemic inflammatory response. *Ultrasound Med Biol* 2019;45:137–47.
- [64] Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. *J Hematol Oncol* 2018;11:104.
- [65] Stride E, Coussios C. Nucleation, mapping and control of cavitation for drug delivery. *Nat Rev Phys* 2019;1:495–509.
- [66] Unger EC, Porter T, Culp W, Labell R, Matsunaga T, Zutshi R. Therapeutic applications of lipid-coated microbubbles. *Adv Drug Deliv Rev* 2004;56:1291–314.
- [67] Sirsi S, Borden M. Microbubble compositions, properties and biomedical applications. *Bubble Sci Eng Technol* 2009;1:3–17.
- [68] Escoffre JM, Deckers R, Bos C, Moonen C. Bubble-assisted ultrasound: application in immunotherapy and vaccination. *Adv Exp Med Biol* 2016;880:243–61.
- [69] Negishi Y, Endo-Takahashi Y, Maruyama K. Gene delivery systems by the combination of lipid bubbles and ultrasound. *Drug Discov Ther* 2016;10:248–55.
- [70] Ferrara K, Pollard R, Borden M. Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. *Annu Rev Biomed Eng* 2007;9:415–47.
- [71] Hu S, Zhang X, Unger M, Patties I, Melzer A, Landgraf L. Focused ultrasound-induced cavitation sensitizes cancer cells to radiation therapy and hyperthermia. *Cells* 2020;9:2595.
- [72] Xu Z, Hall TL, Vlasisvljevich E, Lee Jr. FT. Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound. *Int J Hyperthermia* 2021;38:561–75.
- [73] Qu SB, Worlikar T, Felsted AE, Ganguly A, Beems MV, Hubbard R, et al. Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy. *J Immunother Cancer* 2020;8:e000200.
- [74] Mouratidis PXE, Costa M, Rivens I, Repasky EE, ter Haar G. Pulsed focused ultrasound can improve the anti-cancer effects of immune checkpoint inhibitors in murine pancreatic cancer. *J R Soc Interface* 2021;18:20210266.
- [75] Mathias Jr. W, Tsutsui JM, Tavares BG, Fava AM, Aguiar MOD, Borges BC, et al. Sonothrombolysis in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. *J Am Coll Cardiol* 2019;73:2832–42.
- [76] Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C, et al. Clinical trial of blood–brain barrier disruption by pulsed ultrasound. *Sci Transl Med* 2016;8:343re2.
- [77] Moriyasu F, Itoh K. Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. *AJR Am J Roentgenol* 2009;193:86–95.
- [78] Takahashi M, Hasegawa K, Arita J, Hata S, Aoki T, Sakamoto Y, et al. Contrast-enhanced intraoperative ultrasonography using perfluorobutane microbubbles for the enumeration of colorectal liver metastases. *Br J Surg* 2012;99:1271–7.
- [79] Eisenbrey JR, Forsberg F, Wessner CE, Delaney LJ, Bradigan K, Gummadi S, et al. US-triggered microbubble destruction for augmenting hepatocellular carcinoma response to transarterial radioembolization: a randomized pilot clinical trial. *Radiology* 2021;298:450–7.
- [80] Dimcevski G, Kotopoulis S, Bjanec T, Hoem D, Schjott J, Gjertsen BT, et al. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. *J Control Release* 2016;243:172–81.
- [81] Yuan JY, Ye DZ, Chen S, Chen H. Therapeutic ultrasound-enhanced immune checkpoint inhibitor therapy. *Front Phys* 2021;9:636985.
- [82] Li T, Hu Z, Wang C, Yang J, Zeng C, Fan R, et al. PD-L1-targeted microbubbles loaded with docetaxel produce a synergistic effect for the treatment of lung cancer under ultrasound irradiation. *Biomater Sci* 2020;8:1418–30.
- [83] Huang YH, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. *Cancer Res* 2013;73:2943–8.
- [84] Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. *Cell Res* 2020;30:507–19.
- [85] Zheng J, Huang J, Zhang L, Wang M, Xu L, Dou X, et al. Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment. *Biomater Res* 2023;27:9.
- [86] Banstola A, Jeong JH, Yook S. Immunoadjuvants for cancer immunotherapy: a review of recent developments. *Acta Biomater* 2020;114:16–30.
- [87] Vermaelen K. Vaccine strategies to improve anti-cancer cellular immune responses. *Front Immunol* 2019;10:8.
- [88] Awate S, Babik LA, Mutwiri G. Mechanisms of action of adjuvants. *Front Immunol* 2013;4:114.
- [89] McKee AS, MacLeod MK, Kappler JW, Marrack P. Immune mechanisms of protection: can adjuvants rise to the challenge? *BMC Biol* 2010;8:37.
- [90] Gorbet MJ, Ranjan A. Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: recent progress and challenges in treatment and tracking response to immunotherapy. *Pharmacol Ther* 2020;207:107456.
- [91] Vo MC, Ahn SY, Chu TH, Uthaman S, Pillarisetti S, Uong TNT, et al. A combination of immunoadjuvant nanocomplexes and dendritic cell vaccines in the presence of immune checkpoint blockade for effective cancer immunotherapy. *Cell Mol Immunol* 2021;18:1599–601.
- [92] Hosoya T, Sato-Kaneko F, Ahmadi A, Yao S, Lao F, Kitauro K, et al. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist. *Proc Natl Acad Sci USA* 2018;115:E6836–44.
- [93] Ilovitsh T, Feng Y, Foiret J, Kheirloomoom A, Zhang H, Ingham ES, et al. Low-frequency ultrasound-mediated cytokine transfection enhances T cell recruitment at local and distant tumor sites. *Proc Natl Acad Sci USA* 2020;117:12674–85.
- [94] Li DK, Wang W. Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies. *Oncol Letters* 2020;20:176.
- [95] Borghaei H, Langer CJ, Paz-Ares L, Rodriguez-Abreu D, Halmos B, Garassino MC, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: a pooled analysis of 3 randomized controlled trials. *Cancer* 2020;126:4867–77.
- [96] Xu W, Atkins MB, McDermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. *Nat Rev Urol* 2020;17:137–50.
- [97] Dahan M, Cortet M, Lafon C, Padilla F. Combination of focused ultrasound, immunotherapy, and chemotherapy: new perspectives in breast cancer therapy. *J Ultrasound Med* 2023;42:559–73.
- [98] Huinen ZR, Huijbers EJM, van Beijnum JR, Nowak-Sliwinski P, Griffioen AW. Anti-angiogenic agents—overcoming tumour endothelial cell energy and improving immunotherapy outcomes. *Nat Rev Clin Oncol* 2021;18:527–40.
- [99] Sprinzl MF, Galle PR. Current progress in immunotherapy of hepatocellular carcinoma. *J Hepatol* 2017;66:482–4.
- [100] Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. *Nat Rev Clin Oncol* 2022;19:254–67.